We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-3.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.82B
AUM Growth
-$609M
Cap. Flow
-$347M
Cap. Flow %
-19.1%
Top 10 Hldgs %
52.59%
Holding
435
New
56
Increased
93
Reduced
114
Closed
122

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$9.22M
2
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$7.3M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$7.22M
4
UTHR icon
United Therapeutics
UTHR
+$5.06M
5
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$4.98M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$22.6M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$18.2M
3
VTRS icon
Viatris
VTRS
+$18.1M
4
PXD
Pioneer Natural Resource Co.
PXD
+$15M
5
EW icon
Edwards Lifesciences
EW
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 10.47%
2 Technology 0.45%
3 Consumer Staples 0.1%
4 Industrials 0.09%
5 Materials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRNE
101
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$2.61M 0.14%
300,000
+132,936
+80% +$1.12M
IMUX icon
102
CALL
Immunic
IMUX
$182M
$2.59M 0.14%
6
+5
+500% +$16.3K
TTOO
103
DELISTED
T2 Biosystems, Inc
TTOO
$2.52M 0.14%
46
+15
+48% +$809K
OASM
104
DELISTED
Oasmia Pharmaceutical AB
OASM
$2.4M 0.13%
+663,138
New +$2.61M
CSCI
105
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
$2.39M 0.13%
+5,341
New +$3.35M
BNTC icon
106
Benitec Biopharma
BNTC
$408M
$2.38M 0.13%
2,342
+361
+18% +$498K
PRTK
107
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$2.33M 0.13%
122,613
+5,567
+5% +$106K
OMER icon
108
CALL
Omeros
OMER
$816M
$2.26M 0.12%
1,439
-50
-3% -$691
ANAC
109
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$2.26M 0.12%
20,000
+12,000
+150% +$1.32M
MNTA
110
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$2.23M 0.12%
150,030
+100,000
+200% +$1.67M
BCLI
111
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$2.2M 0.12%
51,302
-5,521
-10% -$227K
PTCT icon
112
PUT
PTC Therapeutics
PTCT
$6.25B
$2.17M 0.12%
669
+550
+462% +$16.2K
VASC
113
PUT
DELISTED
Vascular Solutions Inc
VASC
$2.14M 0.12%
623
+16
+3% +$542
IOVA icon
114
Iovance Biotherapeutics
IOVA
$2.1B
$2.08M 0.11%
270,000
-291,894
-52% -$2.03M
LCI
115
CALL
DELISTED
Lannett Company, Inc.
LCI
$2.07M 0.11%
+129
New +$21.2K
RDHL
116
Redhill Biopharma
RDHL
$4.44M
$2.06M 0.11%
160
-14
-8% -$174K
PLUR icon
117
Pluri
PLUR
$18.1M
$2.05M 0.11%
22,658
+4,228
+23% +$505K
NVRO
118
CALL
DELISTED
NEVRO CORP.
NVRO
$2.03M 0.11%
301
+98
+48% +$5.25K
BCRX icon
119
PUT
BioCryst Pharmaceuticals
BCRX
$2.48B
$2M 0.11%
1,937
+8
+0.4% +$80
LPCN icon
120
Lipocine
LPCN
$17.6M
$1.97M 0.11%
8,954
-2,894
-24% -$607K
MBLY
121
CALL
DELISTED
Mobileye N.V.
MBLY
$1.95M 0.11%
461
-225
-33% -$10.1K
RGNX icon
122
Regenxbio
RGNX
$615M
$1.94M 0.11%
+116,860
New +$2.32M
FOMX
123
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.93M 0.11%
238,400
-4,961
-2% -$37.1K
IOVA icon
124
CALL
Iovance Biotherapeutics
IOVA
$2.1B
$1.89M 0.1%
+2,453
New +$17K
NVIV
125
CALL
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
– –
0
– –
3 4
5
6 7

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2015 Portfolio in Review

As of Q4 2015, Sabby Management held 435 positions worth $1.82B, down 25% from $2.43B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $347M in Q4 2015, closing 122 positions and reducing 114 holdings. Its most notable exit was Biogen, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, down from 13% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Sabby Management opened a new position in Alkermes worth $10.5M.

  • Sabby Management's largest Q4 2015 buy was Alkermes: 131,671 shares worth $10.5M.
  • Sabby Management added most to Tobira Therapeutics, Inc. Common Stock in Q4 2015, an estimated $7.3M increase.
  • Sabby Management's biggest Q4 2015 reduction was Edwards Lifesciences, cutting an estimated $11.6M.
  • Sabby Management fully exited Biogen in Q4 2015, selling an estimated $22.6M.
  • Sabby Management's ten largest holdings make up 53% of its $1.82B portfolio in Q4 2015.
  • Sabby Management opened 56 new positions and closed 122 in Q4 2015.
  • Sabby Management's portfolio value fell 25% quarter-over-quarter to $1.82B.

Based on Sabby Management's 13F filing for Q4 2015, filed 16 Feb 2016.